

QIBA Nuclear Medicine Update Call
FDG-PET/CT & Amyloid BCs combined w/ SPECT representatives
10 April 2015 at 9 AM CT
DRAFT Call Summary

In attendance:

<i>Rathan Subramaniam, MD, PhD (Co-chair, FDG-PET BC)</i>	Paul Kinahan, PhD, FIEEE
<i>John Sunderland, PhD (Co-chair, FDG-PET BC)</i>	Gregory Klein, PhD
<i>Scott Wollenweber, PhD (Co-chair, FDG-PET BC)</i>	Adriaan Lammertsma, PhD
<i>Satoshi Minoshima, MD, PhD (Co-chair, Amyloid BC)</i>	Martin Lodge, PhD
<i>Eric Perlman, MD (Co-chair, Amyloid BC)</i>	Lawrence (Larry) MacDonald, PhD
<i>Anne Smith, PhD (Co-chair, Amyloid BC)</i>	P. David Mozley, MD
Ronald Boellaard, PhD	Nancy Obuchowski, PhD
Ming-Kai Chen, MD, PhD	Amy Perkins, PhD
Susan De Santi, PhD	John Seibyl, PhD
Constantine Gatsonis, PhD	Daniel Sullivan, MD
Howard Higley, PhD	Jean-Luc Vanderheyden, PhD
John Hoffman, MD	Richard Wahl, MD

RSNA

Joe Koudelik
Julie Lisiecki

QIBA Project Proposals for 2015-2016

- Ideas for possible funded project proposals are due **to RSNA staff by April 27th**: qiba@rsna.org
- Dr. Subramaniam proposed a new biomarker Profile for FDG Volumetric markers
 - This would go beyond SUVmax and involve the study of metabolic tumor volume
 - DRO testing and the test-retest group, along with ACRIN 6678, would figure prominently
 - Permission was received last year to contact Merck for datasets supporting this effort
 - Dr. Subramaniam plans to follow up with Dr. Wolfgang Weber and Dr. Barry Siegel for ACRIN 6678 data
- ACRIN imposes stringent requirements for working with their data
 - Travel to ACR HQ to complete the analysis on site, along with costs associated with bringing additional readers to Philadelphia must be considered
 - To control budget, the possibility of allowing readers to access data remotely is being considered
 - ACR clearance would be needed
 - Using automated reader algorithms, instead of using human readers, was also suggested as a test
 - ACR has a MIMVISTA reader package; it is uncertain whether or not this package is automatic
 - Dr. Subramaniam to follow up with ACR re: level of automation
 - A test of the software may be possible, using either a physical phantom or DRO to test volume and FDG
 - Dr. Kinahan to follow up with Dr. Pierce regarding possibility of modifying the DRO
 - Dr. Perlman suggested that a “challenge” similar to the QIBA 3A challenge for CT Volumetry testing different algorithms in an anonymized fashion might be another project idea
- Dr. Lodge suggested a project to evaluate PET image reconstruction parameters
 - Currently, a wide range of parameters exist, making selection more difficult with a wide range of scanners
 - Some guidance on measuring spatial resolution in a systematic and meaningful way may be helpful
- A software trial with PIP data was also suggested
 - Dr. Perlman to inquire whether or not Piramal may be willing to share data.
- Another suggested project was “Diagnostic Inter-Rater Variability” with a receiver or rater role for QIBA
 - As there are discrepancies between visual and quantitative analysis, the FDA is interested in projects that may provide a better understanding of quantitative measurement

Action items:

- BC co-chairs need slides from Task Force Leaders – for presentations at the QIBA Annual Meeting

- Proposal champions are needed for project proposals; reminder to plan for indirect costs

Proposed Nuclear Medicine Calls (Fridays, 9 am CT):

- **April 17:** (proposed) SPECT Biomarker Ctte
- **April 24:** PET Amyloid Biomarker Ctte
- **May 1:** FDG-PET Biomarker Ctte {Planning for the QIBA Annual Meeting for those representatives who will be attending.}
- **May 8:** No call (day after the QIBA Annual Meeting)
- **May 15:** Combined Nuclear Medicine Call Update (*FDG-PET, Amyloid, SPECT (?)*)
- **May 22:** Amyloid Biomarker Ctte
- **May 29:** (proposed) SPECT Biomarker Ctte